CNX Therapeutics Launches MISABRI PR (Pregabalin) Prolonged-Release Tablets for Neuropathic Pain Management in the UK
London, Monday 10 March 2025 – CNX Therapeutics Limited (“CNX Therapeutics”) today announced the launch of MISABRI PR (Pregabalin) prolonged-release tablets, a once-daily treatment option for adults with peripheral and central neuropathic pain. Developed in partnership with Adalvo, MISABRI PR is available in three dosage strengths (82.5mg, 165mg and 330mg), offering a flexible dose range to meet individual patient needs (Ref SmPC).
Neuropathic pain, a condition affecting nearly 10% of the UK population1, can significantly impact quality of life and is often challenging to manage. MISABRI PR has been developed to offer patients a convenient and effective treatment option, with the added benefit of once-daily dosing to support and simplify treatment regimens.
The launch of MISABRI PR in the UK highlights CNX Therapeutics’ commitment to advancing innovative treatments within the Central Nervous System (CNS) space and delivering value-added medicines. By introducing this therapy, CNX is addressing an unmet need in neuropathic pain management, reinforcing its dedication to supporting healthcare providers to improve patient outcomes.
Guy Clark, CEO of CNX Therapeutics, said: “The launch of MISABRI PR marks an important milestone in our commitment to addressing unmet needs for patients and prescribers. By offering a once-daily formulation, we aim to provide healthcare professionals with a valuable tool to help improve patient outcomes in the management of neuropathic pain. Neuropathic pain can be debilitating, and we believe MISABRI PR will play a key role in supporting patients and their clinicians in managing this complex condition.”
This initiative aligns with CNX’s mission to improve access to vital medicines and strengthen its footprint in key European markets, reinforcing its commitment to delivering high-quality, patient-centric solutions across the continent.
The clinical development programme for pregabalin, the active ingredient in MISABRI PR, involved over 8,900 patients, including more than 5,600 participants in double-blind, placebo-controlled trials. The safety profile of pregabalin is well-established, with adverse reactions typically mild to moderate in intensity. The most commonly reported adverse reactions leading to discontinuation were dizziness and somnolence.(Ref SmPC)
"Being first and only to market with Pregabalin PR in Europe highlights our strength in delivering high-value, differentiated treatments," said Anil Okay, CEO of Adalvo. "This launch reflects our agility and market expertise, ensuring high-quality differentiated solutions for patients and partners."
MISABRI PR is now available in the UK. Healthcare professionals are encouraged to review the full prescribing information, which includes details on dosage, contraindications, and adverse event reporting.
